Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 10/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | YES1 | P07947 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35212115 | 0.77 | NFE2L2 (0.70) | NFE2L2HPGDGRM2HRH3 | |
| SCHEMBL30674531 | 0.77 | NFE2L2 (0.70) | NFE2L2HPGDGRM2HRH3 | |
| SCHEMBL15004522 | 0.75 | NFE2L2 (0.67) | NFE2L2HPGDGRM2HRH3 | |
| SCHEMBL3332404 | 0.75 | CA12 (0.47) | HRH3LTA4H | |
| SCHEMBL8274997 | 0.74 | NFE2L2 (0.66) | NFE2L2HPGDGRM2HRH3LTA4H | |
| SCHEMBL30674771 | 0.73 | NFE2L2 (0.70) | NFE2L2HPGDGRM2HRH3 | |
| SCHEMBL3303080 | 0.73 | CYP3A4 (0.44) | — | |
| SCHEMBL8276935 | 0.72 | NFE2L2 (0.63) | NFE2L2HPGDGRM2HRH3LTA4H | |
| SCHEMBL9264667 | 0.71 | NQO1 (0.50) | HPGDLTA4H | |
| SCHEMBL10212076 | 0.71 | NFE2L2 (0.66) | NFE2L2HPGDGRM2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | NFE2L2 1770/4885HPGD 195/4885GRM2 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.